SciCombinator

Discover the most talked about and latest scientific content & concepts.

SC Navada and LR Silverman
Abstract
Hypomethylating agents (HMAs) are the standard of care for patients with higher-risk myelodysplastic syndromes (MDS), but patients who relapse or are refractory have a poor prognosis with an estimated survival of 4-6 months. Rigosertib, a RAS mimetic that inhibits the phophoinositide 3-kinase and polo-like kinase pathways, has been tested in patients with higher-risk MDS following treatment with HMAs, where there are no approved second-line therapies.
Tweets*
2
Facebook likes*
0
Reddit*
0
News coverage*
4
Blogs*
0
SC clicks
0
Concepts
Acute myeloid leukemia, Syndromes, Myelodysplastic syndrome
MeSH headings
-
comments powered by Disqus

* Data courtesy of Altmetric.com